Pentixapharm Raises EUR 20.4 Million Through Capital Increase

Pentixapharm Holding AG successfully completed a capital increase, securing approximately EUR 20.4 million from the full placement of 11,020,212 new shares. Each share was priced at EUR 1.85. The funds will support the U.S. Phase 3 PANDA study, evaluating [⁶⁸Ga]Ga-PentixaFor for primary aldosteronism subtyping. This follows key FDA milestones, including Study May Proceed and Fast Track Designation.

The company plans to initiate PANDA in the second half of 2026, with Fast Track facilitating FDA interactions. The financing will also aid in expanding U.S. operations and developing Pentixapharm's CXCR4-based theranostic platform.

Notably, 82.5% of shares were subscribed during the rights offering, generating EUR 16.8 million. Remaining shares were placed with institutional investors. The transaction was managed by BankM AG and NuWays, with net proceeds expected to reach EUR 19.65 million after costs.